Form 4: Acadia Pharmaceuticals Executive Sells Shares to Cover Tax Obligations

Mark C. Schneyer, EVP and CFO of Acadia Pharmaceuticals, sold shares to cover withholding taxes related to vesting restricted stock units.

Summary

• On June 8, 2024, Mark C. Schneyer acquired 1,893 shares of common stock through the vesting of restricted stock units.
• On June 10, 2024, Schneyer sold 975 shares of Acadia Pharmaceuticals' common stock at a price of $14.79 per share.
• The sale was executed to cover withholding taxes and tax-related items associated with the vesting of restricted stock units.
• Following the reported transactions, Schneyer beneficially owns 34,564 shares of Acadia Pharmaceuticals' common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to insider trading. The sentiment is neutral as it reflects routine transactions.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across publicly traded companies.
• Comparing the percentage of shares sold to total holdings with peers like Biogen, Amgen, or Vertex Pharmaceuticals would provide context on the magnitude of this transaction.

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some shareholders, although it is a common practice for covering tax obligations.
• The impact on other stakeholders is likely minimal.

Key Dates